Korsana Biosciences, Inc. KRSA
Korsana Biosciences, Inc. (Nasdaq: KRSA) is a CNS/neurology/psychiatry drug developer. Its lead program, KRSA-028, is in Pre-clinical for Alzheimer's disease. Its next catalyst on record is KRSA-028: CTN (Australia) or CTA (New Zealand) submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KRSA-028 — CTN (Australia) or CTA (New Zealand) submission (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KRSA-028 | Alzheimer's disease | antibody | Pre-clinical |
| Undisclosed program(s) | neurodegenerative diseases (unspecified) | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.